Can a lung cancer drug still fight back after failing?
NCT ID NCT07400575
Summary
This study looks back at medical records to see if continuing the drug anlotinib helps control advanced lung cancer, even after the cancer has started growing again. It will include about 350 people with specific types of lung cancer who kept taking anlotinib or switched to other treatments after their disease progressed. The main goal is to see if this approach can slow the cancer's growth and is safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.